Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Jeffrey Graham


Published on

  • Be the first to comment

  • Be the first to like this

Jeffrey Graham

  1. 1. IVEY ENTREPRENEURSHIP CROSS-ENTERPRISE LEADERSHIP CENTRE Medical Technology Innovation Public Policy Drivers for Innovation & Adoption of Medical Technologies <ul><li>Jeffrey S. Graham </li></ul><ul><li>Borden Ladner Gervais LLP </li></ul><ul><li>416-367-6174 </li></ul><ul><li>[email_address] </li></ul>
  2. 2. Outline <ul><li>The current Canadian public policy environment </li></ul><ul><li>Investment incentives </li></ul><ul><li>R&D incentives </li></ul><ul><li>Procurement incentives </li></ul><ul><li>Proposed direction </li></ul>
  3. 3. Investment Incentives <ul><li>Provincial (Illustrative): </li></ul><ul><li>Ontario Venture Capital Fund </li></ul><ul><li>Health Technology Exchange </li></ul><ul><li>Ontario Emerging Technologies Fund </li></ul><ul><li>Ontario Innovation Demonstration Fund </li></ul>
  4. 4. R&D Incentives <ul><li>SR & ED - Federal 20% non-refundable tax credit for public companies and a 35% refundable tax credit for private companies. </li></ul><ul><li>Granting programs and agencies: </li></ul><ul><ul><li>Genome Canada, CIHR, NRC, NSERC, IRAP </li></ul></ul>
  5. 5. Procurement Incentives <ul><li>Provincial Plan Listing Decisions </li></ul><ul><li>Quebec “15 year rule” </li></ul>
  6. 6. Proposed Direction <ul><ul><li>Implementing an effective right of appeal for innovators within Canada </li></ul></ul><ul><ul><li>Enhancing innovator Data Protection to U.S. and EU levels </li></ul></ul><ul><ul><li>Implementing a Patent Term Restoration system similar to that of our G7 competitors </li></ul></ul><ul><ul><li>Improving Health Canada regulatory review performance; </li></ul></ul><ul><ul><li>Targeting higher public reimbursement rates for innovative medicines and vaccines. </li></ul></ul><ul><ul><li>Expanding the definition of eligible research to better capture all aspects of clinical research, including all investments in clinical trials, as well as complementary investments in other forms of research partnerships not currently eligible for SR&ED credits; </li></ul></ul><ul><ul><li>Create flow through shares program for medical technologies; </li></ul></ul><ul><ul><li>Consideration of a refundable wage credit for R&D workers to better target and sustain employment in innovation. </li></ul></ul>